Q-omics provides the consensus-scored SPRR2G profile across patient tissues and cancer cell-line models. SPRR2G expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, SPRR2G is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, SPRR2G RNA expression shows 9,669 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ESCA, and LUSC as cancer lineages where SPRR2G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRR2G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRR2G survival associations across molecular data types. SPRR2G RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRR2G RNA expression–survival associations across cancer types. High SPRR2G expression shows unfavorable associations in ACC, TGCT and SCLC, but favorable associations in ESCA, UCS and LGG. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .013). Together, the overview and detailed table identify ESCA as the clearest survival context for SPRR2G RNA expression.
This table summarizes SPRR2G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPRR2G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRR2G shows lower tumor expression in LUAD and higher tumor expression in LUSC and HNSC. The LUSC box plot shows higher SPRR2G RNA expression in tumor versus normal tissue (log2 FC = +3.624, t-test p < 0.001).
This table shows molecular features associated with SPRR2G in patient tissues and cancer cell lines. In patient samples, SPRR2G shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRR2G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
